When facing early breast cancer, the goal of treatment before surgery is often to shrink the tumor as much as possible. This study looked at 207 patients with a specific type of breast cancer called HER2-positive and hormone receptor-positive. Researchers compared two different paths: one using chemotherapy (paclitaxel) combined with targeted drugs, and another using hormone therapy instead of chemotherapy.
The results showed that the group receiving chemotherapy had a much higher rate of pathologic complete response, which means the tumor was completely gone before surgery. In that group, 56.4% achieved this result compared to 23.7% in the hormone therapy group. While both groups showed high rates of survival over five years, the chemotherapy group performed better at clearing the cancer before the operation.
It is important to note that this was a Phase II trial, which means it is an earlier stage of testing rather than a large-scale final confirmation. However, the study confirms that these treatments are well-tolerated by patients. Because every person's health needs are different, patients should talk to their doctors about whether chemotherapy or hormone therapy is the best fit for their specific situation.
